Abcuro, Inc.
- Country
- ๐บ๐ธUnited States
- Ownership
- Holding
- Established
- 2015-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.abcuro.com
Clinical Trials
6
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)โข Click on a phase to view related trials
Long-term Extension Study of Ulviprubart (ABC008) in Subjects With Inclusion Body Myositis
- Conditions
- Inclusion Body Myositis (IBM)
- Interventions
- First Posted Date
- 2024-06-10
- Last Posted Date
- 2025-07-28
- Lead Sponsor
- Abcuro, Inc.
- Target Recruit Count
- 270
- Registration Number
- NCT06450886
- Locations
- ๐บ๐ธ
Neuromuscular Research Center, Phoenix, Arizona, United States
๐บ๐ธUniversity of California Irvine Medical Center (UCIMC) - Amyotrophic Lateral Sclerosis (ALS) and Neuromuscular Center, Irvine, California, United States
๐บ๐ธKeck Hospital of USC, Los Angeles, California, United States
A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis
- First Posted Date
- 2023-02-10
- Last Posted Date
- 2025-06-10
- Lead Sponsor
- Abcuro, Inc.
- Target Recruit Count
- 231
- Registration Number
- NCT05721573
- Locations
- ๐บ๐ธ
Neuromuscular Research Center, Phoenix, Arizona, United States
๐บ๐ธUniversity of California Irvine Medical Center (UCIMC) - Amyotrophic Lateral Sclerosis (ALS) and Neuromuscular Center, Irvine, California, United States
๐บ๐ธKeck Hosptial of USC, Los Angeles, California, United States
ABC008 in Subjects with T-cell Large Granular Lymphocytic Leukemia (T-LGLL)
- Conditions
- T-cell Large Granular Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2022-09-08
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Abcuro, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT05532722
- Locations
- ๐บ๐ธ
City of Hope, Duarte, California, United States
๐บ๐ธUniversity of Southern California, Los Angeles, California, United States
๐บ๐ธMassachusetts General Hospital, Boston, Massachusetts, United States
A Phase 1 Study of ABC008 in Ascending (Single Ascending Dose/Multiple Ascending Dose) Study in Patients with (IBM)
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Abcuro, Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT04659031
- Locations
- ๐ฆ๐บ
Royal Adelaide Hospital, Adelaide, South Australia, Australia
๐ฆ๐บRoyal Brisbane, Herston, Australia
๐ฆ๐บPerron Institute, Perth, Australia